Offering a variety of integrated visualization tools, the SiteRite 9 Ultrasound System reportedly enables the insertion of vascular access devices regardless of user experience level.
For clinicians placing central venous catheters, peripherally inserted central catheters (PICCs) and IV lines, BD has launched the SiteRite™ 9 Ultrasound System.
In addition to a 15.6-inch touch screen with enhanced image quality, the SiteRite 9 Ultrasound System enables real-time needle monitoring with the Cue™ Needle Tracking System and guided catheter tip navigation with the Sherlock 3CG+™ Tip Confirmation System, according to BD.
The company added that the system also facilitates appropriate catheter selection with a combination of automated vessel assessment tools and vessel measurement capability.
"Our latest innovation in ultrasound technology is designed to make vascular access care delivery easier and more efficient for clinicians — whether they've been on the job for years or are new to the field," said Eric Borin, the worldwide president of Medication Delivery Solutions at BD. " … We've developed a best-in-class solution to aid in insertion success on the first attempt and reduce the need for repeated needlesticks to deliver a better care experience for everyone involved."
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.